de Bruin Béatrice, Kuhnast Bertrand, Hinnen Françoise, Yaouancq Loïc, Amessou Mohamed, Johannes Ludger, Samson Alain, Boisgard Raphaël, Tavitian Bertrand, Dollé Frédéric
Service Hospitalier Frédéric Joliot, Département de Recherche Médicale, CEA/DSV, 4 place du Général Leclerc, F-91401 Orsay, France.
Bioconjug Chem. 2005 Mar-Apr;16(2):406-20. doi: 10.1021/bc0497463.
FPyME (1-[3-(2-fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione) was designed as a [(18)F]fluoropyridine-based maleimide reagent for the prosthetic labeling of peptides and proteins via selective conjugation with a thiol (sulfhydryl) function. Its pyridinyl moiety carries the radioactive halogen (fluorine-18) which can be efficiently incorporated via a nucleophilic heteroaromatic substitution, and its maleimido function ensures the efficient alkylation of a free thiol function as borne by cysteine residues. [(18)F]FPyME (HPLC-purified) was prepared in 17-20% non-decay-corrected yield, based on starting [(18)F]fluoride, in 110 min using a three-step radiochemical pathway. The developed procedure involves (1) a high-yield nucleophilic heteroaromatic ortho-radiofluorination on [3-(3-tert-butoxycarbonylaminopropoxy)pyridin-2-yl]trimethylammonium trifluoromethanesulfonate as the fluorine-18 incorporation step, followed by (2) rapid and quantitative TFA-induced removal of the N-Boc-protective group and (3) optimized maleimide formation using N-methoxycarbonylmaleimide. Typically, 4.8-6.7 GBq (130-180 mCi) of radiochemically pure [(18)F]FPyME ([(18)F]-1) could be obtained after semipreparative HPLC in 110 min starting from a cyclotron production batch of 33.3 GBq (900 mCi) of [(18)F]fluoride (overall radiochemical yields, based on starting [(18)F]fluoride: 28-37% decay-corrected). [(18)F]FPyME ([(18)F]-1) was first conjugated with a small model hexapeptide ((N-Ac)KAAAAC), confirming the excellent chemoselectivity of the coupling reaction (CH(2)SH versus CH(2)NH(2)) and then conjugated with two 8-kDa proteins of interest, currently being developed as tumor imaging agents (c-AFIM-0 and c-STxB). Conjugation was achieved in high yields (60-70%, isolated and non-decay-corrected) and used optimized, short-time reaction conditions (a 1/9 (v/v) mixture of DMSO and 0.05 M aq Tris NaCl buffer (pH 7.4) or 0.1 M aq PBS (pH 8), at room temperature for 10 min) and purification conditions (a gel filtration using a Sephadex NAP-10 cartridge or a SuperDex Peptide HR 10/30 column), both compatible with the chemical stability of the proteins and the relatively short half-life of the radioisotope concerned. The whole radiosynthetic procedure, including the preparation of the fluorine-18-labeled reagent, the conjugation with the protein and the final purification took 130-140 min. [(18)F]FPyME ([(18)F]-1) represents a new, valuable, thiol-selective, fluorine-18-labeled reagent for the prosthetic labeling with fluorine-18 of peptides and proteins. Because of its excellent chemoselectivity, [(18)F]FPyME offers an interesting alternative to the use of the nonselective carboxylate and amine-reactive [(18)F]reagents and can therefore advantageously be used for the design and development of new peptide- and protein-based radiopharmaceuticals for PET.
FPyME(1-[3-(2-氟吡啶-3-基氧基)丙基]吡咯-2,5-二酮)被设计为一种基于[(18)F]氟吡啶的马来酰亚胺试剂,用于通过与硫醇(巯基)官能团选择性共轭对肽和蛋白质进行假体标记。其吡啶基部分带有放射性卤素(氟-18),可通过亲核杂芳族取代有效引入,其马来酰亚胺官能团可确保半胱氨酸残基所携带的游离硫醇官能团的有效烷基化。[(18)F]FPyME(经高效液相色谱纯化)基于起始[(18)F]氟化物,采用三步放射化学途径,在110分钟内以17 - 20%的非衰变校正产率制备。所开发的方法包括:(1) 在[3-(3-叔丁氧羰基氨基丙氧基)吡啶-2-基]三甲基铵三氟甲磺酸盐上进行高产率的亲核杂芳族邻位放射性氟化作为氟-18引入步骤,随后(2) 用三氟乙酸快速定量地去除N - Boc保护基团,以及(3) 使用N - 甲氧基羰基马来酰亚胺优化马来酰亚胺的形成。通常,从回旋加速器生产的一批33.3 GBq(900 mCi)的[(18)F]氟化物开始,在110分钟内经半制备高效液相色谱后,可获得4.8 - 6.7 GBq(130 - 180 mCi)放射化学纯的[(18)F]FPyME([(18)F]-1)(基于起始[(18)F]氟化物的总放射化学产率:28 - 37%衰变校正)。[(18)F]FPyME([(18)F]-1)首先与一个小的模型六肽((N - Ac)KAAAAC)共轭,证实了偶联反应(CH(2)SH对CH(2)NH(2))具有优异的化学选择性,然后与两种感兴趣的8 kDa蛋白质共轭,这两种蛋白质目前正被开发用作肿瘤显像剂(c - AFIM - 0和c - STxB)。共轭反应以高产率(60 - 70%,分离且非衰变校正)实现,并采用了优化的短时间反应条件(二甲基亚砜与0.05 M Tris - NaCl水溶液缓冲液(pH 7.4)或0.1 M PBS水溶液(pH 8)的1/9(v/v)混合物,在室温下反应十分钟)和纯化条件(使用Sephadex NAP - 10柱或SuperDex Peptide HR 10/30柱进行凝胶过滤),这两种条件都与蛋白质的化学稳定性以及相关放射性同位素相对较短的半衰期相兼容。整个放射合成过程,包括氟-18标记试剂的制备、与蛋白质的共轭以及最终纯化,耗时130 - 140分钟。[(18)F]FPyME([(18)F]-1)代表一种新型、有价值、硫醇选择性的、用于肽和蛋白质的氟-18标记的假体标记试剂。由于其优异的化学选择性,[(18)F]FPyME为使用非选择性的羧酸盐和胺反应性[(18)F]试剂提供了一种有趣的替代方法,因此可有利地用于设计和开发用于正电子发射断层显像(PET)的新型基于肽和蛋白质的放射性药物。